Date: 2015-09-19 Time: 1:00 – 4:00 PM
Location: Hanqi Investment Inc., 1633 Bayshore Highway Suite 280 Burlingame, CA 94010
Over the past few years, there have been remarkable advances in DNA detection and sequencing technologies that enabled faster and better diagnostics developed for liquid biopsies. Liquid biopsies have now emerged as promising tools that are safer and cheaper than traditional tissue biopsies to survey health and disease state. For the first time, we are now able to obtain a wealth of information from blood and urine derived circulating DNA fragments that could revolutionize research and patient care. Began with prenatal screening, these technologies now allow physicians to make early disease diagnosis, monitor progression, and predict treatment benefits. This workshop will be led by founders and leaders of many prominent companies which have pioneered the frontiers of peripheral monitoring. We will discuss the science and applications behind these novel technologies as well as the trials and tribulations of building a life science start-up.
|1:00 – 1:25 pm||Registration, networking, workshop introduction|
|1:25 – 1:50 pm||Mike Schwartz, Co-founder and VP of Marketing, Fluxion Biosciences|
|Liquid biopsy innovations for oncology using sequencing of circulating tumor cells|
|1:50 – 2:15 pm||Paul Tang, Co-founder, AccuraGen|
|Realizing the fantasy of liquid biopsy|
|2:15 – 2:40 pm||Mojgan Haddad, former Sr. Director, Bioinformatics and Analytics, Health Tell|
|HIV Drug Resistance Diagnostics: Path of Discovery to Clinical Application|
|2:40 – 3:00 pm||Break|
|3:00 – 3:25 pm||John Waldeisen, Co-founder and CEO, DiAssess|
|My Life as an Entrepreneur|
|3:25 – 3:50 pm||Nikolay Sergeev, R & D leader, Natera|
|Applications of Massively-Multiplexed PCR for Liquid Biopsy|
|3:50 – 4:00 pm||Wrap-up|
Michael Schwartz, Co-Founder and VP, Marketing, Fluxion Biosciences
Michael co-founded Fluxion Biosciences in 2006 to commercialize novel microfluidic technology for clinical diagnostic applications. As VP Marketing, he has led the commercial and product strategies for several product lines, including the IsoFlux System for liquid biopsy applications. Prior to Fluxion, he held product management and development roles with Advanced Stent Technologies (acquired by Boston Scientific), Converge Medical, and Biocardia (IPO pending). Michael holds a MS in Biomedical Engineering from Columbia University, and a BS in Bioengineering from UC Berkeley. He holds 10 patents and has authored numerous publications in the field of oncology diagnostics.
Paul Tang, PhD, Co-Founder, AccuraGen, Inc
Dr. Tang co-founded AccuraGen in 2013, together with a group of fellow scientists in the Bay area, to improve rare allele detection in circulating cell-free DNA. Prior to embarking on this venture, Dr. Tang was a technical lead at the Genomics Core Facility at University of California, San Francisco (UCSF), where he contributed to an early foundation of Genomics Medicine Initiative at UCSF, led by Dr. Bob Nussbaum. From 2010-2013, when he was a postdoc at Dr. Pui-Yan Kwok lab at UCSF, he has co-authored more than 10 peer reviewed papers in reputed journals, utilizing a variety of genomic technologies to understand different human diseases. Dr. Tang holds a B.S. in Bioinformatics and PhD in Genetics from the University of Hong Kong.
Mojgan Haddad, PhD
Dr. Haddad held the position of Senior Director, Bioinformatics and Analytics at HealthTell, Inc. Prior to that, Mojgan served in various roles at Monogram Biosciences, a LabCorp company, including Director of Bioinformatics and Biostatistics, and Director of Software Engineering, from 2000 to 2013. Mojgan received her PhD in Computer Science and Medical Informatics from Vienna University of Technology in Austria, and performed her postdoctoral study at UCSF in the area of Mathematical and Computational Biology. Dr. Haddad serves as an editor for a few journals, and has published extensively in the area of data science for virology, oncology, and personalized medicine.
John R. Waldeisen, PhD; CEO & Co-founder, Diassess Inc.
John is a co-founder of Diassess, a molecular diagnostic startup developing the next generation of rapid DNA testing. Since the founding of the company in 2013, John has led the company through technology development, organized on-going clinical studies with local hospitals, negotiated with strategic partners, and has raised significant VC funding for Diassess. John graduated summa cum laude from Penn State University and received his PhD in Bioengineering from UC Berkeley. He has 10 publications in peer-reviewed journals, 5 pending patents, and co-authored more than $3.5M in diagnostic grants from the Gates Foundation, DARPA, NIH, and NSF over the past 6 years. He is a StartX and YCombinator alumnus.
Nikolay Sergeey, PhD. R&D Leader, Natera
As a leader in the field of NGS method development for liquid biopsy and molecular diagnostics, Dr. Sergeev has served as the leader of Research and Development at Natera since 2014. Prior to joining Natera, Dr. Sergeev was responsible for development, clinical validation, and the launching of automated workflow for the Guardant360 test. Between 2002 and 2012, Dr. Sergeev held several leadership roles in Government and Industry, including Biosensors Laboratory Leader at the FDA/CDRH, Senior Staff Scientist at Life Technologies, and Principal Scientist at New Venture Strategies Inc. Nikolay holds a MS in Biotechnology and a PhD in Bioorganic Chemistry from a leading research institute at the Russian Academy of Sciences. He has authored more than 15 peer-reviewed papers and book chapters and holds multiple patents related to sample preparation and advanced molecular methods.
Organizers: CABS Science & Technology Committee